Does Anthem Cover Lantus? A Plain-Language Insurance Guide

What Is Lantus and Why Does Insurance Tier Matter?

Lantus is a long-acting, basal insulin analog used to manage both type 1 and type 2 diabetes. The FDA approved it on April 20, 2000, and it remains one of the most prescribed basal insulins in the United States. Approximately 37.3 million Americans live with diabetes, and a significant portion depend on basal insulin therapy to keep fasting glucose within a safe range. [1]

Insurance formulary tiers determine how much you pay out of pocket for a covered drug. A Tier 1 drug (generic or preferred) costs the least. A Tier 3 or Tier 4 drug (non-preferred brand) costs substantially more, and some plans require you to fail a cheaper alternative before the plan pays for the higher-tier medication at all. That process is called step therapy.

Anthem uses a tiered formulary system across its commercial, Medicare Advantage, and Medicaid managed-care lines. The exact tier for Lantus varies by product line. On most commercial plans reviewed for this article, Lantus sits at Tier 3, meaning your copay or coinsurance will be higher than it would be for a preferred biosimilar insulin glargine. On some Medicare Advantage plans, Lantus may not appear on the formulary at all, because the plan has substituted a therapeutically equivalent biosimilar instead.

The practical takeaway: never assume your plan covers Lantus at a low cost-share just because it covered it last year. Anthem updates its formularies annually, and biosimilar adoption has accelerated since 2021.

How to Check Your Specific Anthem Plan's Lantus Coverage

Checking your personal formulary takes about five minutes and avoids expensive surprises at the pharmacy.

Step 1. Log in to your Anthem member portal at anthem.com and manage to "Find a Drug" or "Formulary Search." Enter "insulin glargine" or "Lantus" in the search bar.

Step 2. Confirm your plan year. Formularies reset on January 1 each year, and mid-year updates are permitted for biosimilar additions.

Step 3. Note the tier, any "QL" (quantity limit), "PA" (prior authorization), or "ST" (step therapy) flags next to the listing.

Step 4. Call the member services number on the back of your Anthem card if the online tool is unclear. Ask specifically: "Is Lantus on my formulary, what tier is it, and does it require prior authorization or step therapy?"

The FDA's Orange Book lists all approved insulin glargine products and their interchangeability designations, which is useful context when discussing alternatives with your pharmacist. [2]

Prior Authorization: When Anthem Requires Extra Steps

Prior authorization (PA) means your prescriber must submit clinical documentation to Anthem before the plan will cover the drug at the formulary price. For Lantus specifically, Anthem's PA criteria on many commercial plans require evidence that the patient has been diagnosed with type 1 or type 2 diabetes and, in some cases, that the patient has tried or has a documented reason to avoid a preferred biosimilar insulin glargine.

Step therapy adds another layer. If your plan requires step therapy, you may need to use Basaglar, Semglee, or another preferred glargine product for a defined period (often 30 to 90 days) before Lantus is authorized. The FDA has designated Semglee as interchangeable with Lantus, meaning a pharmacist can substitute it without a new prescription in states that allow automatic substitution. [3]

To request a PA, your endocrinologist or primary care physician should:

1. Submit Anthem's PA request form, available through the provider portal.
2. Include your most recent HbA1c, current insulin regimen, and any documented adverse reactions or contraindications to alternative products.
3. Attach clinical notes showing that glycemic control is inadequate or that a biosimilar switch could pose a safety risk.

Anthem is required to respond to urgent PA requests within 72 hours and to standard requests within 15 calendar days under most state regulations. If denied, you have the right to appeal.

A 2022 analysis published in JAMA Internal Medicine found that insurer prior authorization requirements for insulin were associated with greater patient cost burden and increased rates of cost-related non-adherence, underscoring why resolving PA issues quickly matters clinically. [4]

What Anthem Pays: Tiers, Copays, and Coinsurance

Anthem does not publish a single universal copay for Lantus because the amount depends on your specific plan design, your deductible status, and whether you are in the initial coverage phase, the coverage gap, or catastrophic coverage (for Medicare Part D plans).

For commercially insured Anthem members, typical out-of-pocket ranges are:

• Tier 2 (preferred brand, if Lantus is listed there): $40, $80 per 30-day supply after deductible
• Tier 3 (non-preferred brand, the most common placement): $80, $150 per 30-day supply after deductible
• Tier 4 or specialty tier: $150 or more, or 20 to 30% coinsurance, whichever is higher

Before your deductible is met, you may pay the full negotiated rate for Lantus, which can range from $250 to $350 per vial at major pharmacy chains, depending on Anthem's contracted rate with the pharmacy.

For Medicare Advantage members, the Inflation Reduction Act (IRA), signed into law in August 2022, caps cost-sharing for covered insulin products at $35 per month starting January 1, 2023. The CMS confirmed this cap applies to all Part D-covered insulins, including Lantus when it appears on the plan's formulary. [5] If your Medicare Advantage plan does not list Lantus, the $35 cap still applies to whichever insulin glargine product is on the formulary.

For Medicaid members enrolled in an Anthem-managed Medicaid plan, cost-sharing is typically minimal (often $1, $4 per prescription), but formulary restrictions may still apply, and your state Medicaid agency sets the rules. Check your state's Medicaid preferred drug list directly.

Biosimilar Insulin Glargine Products on Anthem Formularies

The biosimilar market for insulin glargine has grown considerably since 2021. Understanding these alternatives helps you have a productive conversation with both your prescriber and Anthem.

Basaglar (insulin glargine-yjpf). Approved by the FDA in December 2015 and manufactured by Eli Lilly, Basaglar was the first insulin glargine biosimilar in the U.S. It is not designated interchangeable with Lantus, but head-to-head clinical data show comparable glycemic outcomes. The ELEMENT-1 and ELEMENT-2 trials (N=535 and N=756, respectively) demonstrated non-inferiority of Basaglar versus Lantus on HbA1c reduction at 24 weeks. [6]

Semglee (insulin glargine-yfgn). Manufactured by Viatris and Biocon, Semglee received FDA interchangeable biosimilar designation in July 2021. That designation means pharmacists in most states can dispense it in place of a Lantus prescription without calling the prescriber. Semglee's list price at launch was approximately 65% lower than Lantus's branded list price.

Rezvoglar (insulin glargine-aglr). Also manufactured by Eli Lilly, Rezvoglar launched in January 2023 at a list price of $92 per package (5 KwikPens), representing the steepest list-price cut in the insulin glargine category at that time.

Many Anthem commercial formularies now list Semglee or Rezvoglar as the preferred Tier 1 or Tier 2 insulin glargine product, which is why Lantus has moved to Tier 3 on so many plans. Switching to an interchangeable biosimilar is clinically reasonable for most patients with type 2 diabetes who are stable on basal insulin, but patients with type 1 diabetes or complex titration histories should discuss any switch with their endocrinologist before the pharmacy makes an automatic substitution.

The framework below summarizes how to decide whether to accept a biosimilar switch or pursue a PA for brand Lantus:

| Situation | Recommended Action | |---|---| | Stable type 2 diabetes, new to basal insulin | Accept interchangeable biosimilar (Semglee or Rezvoglar) at Tier 1 cost-share | | Established on Lantus, well-controlled HbA1c, type 2 | Discuss switch with prescriber; try biosimilar first given equivalent efficacy data | | Type 1 diabetes with variable absorption history | Ask prescriber to submit PA citing clinical rationale for brand continuity | | Documented adverse reaction to a biosimilar excipient | Prescriber submits PA with reaction documentation; strong basis for approval | | Medicare Part D enrollee | All covered insulins capped at $35/month; choose whichever glargine is on formulary |

What to Do If Anthem Denies Lantus Coverage

A denial is not the end of the road. You have several formal and informal options.

Step 1: Prescriber-to-prescriber peer review. Ask your doctor's office to request a peer-to-peer review with the Anthem medical director. This is a phone call between your physician and Anthem's reviewing physician. Data from the American Medical Association suggest peer-to-peer calls overturn denials roughly 75% of the time when the prescriber can cite specific clinical reasons. Your prescriber should reference the American Diabetes Association Standards of Medical Care in Diabetes to support the clinical necessity of a specific insulin formulation. [7]

Step 2: Internal appeal. If peer review fails, file a formal internal appeal within the timeframe stated in the denial letter (usually 30 to 60 days). Include chart notes, lab results (HbA1c trend, fasting glucose logs), and a letter from your prescriber explaining why Lantus is medically necessary for you specifically.

Step 3: External independent review. If Anthem upholds the denial after internal appeal, you can request an external review by an independent review organization (IRO). Federal law under the Affordable Care Act requires insurers to comply with IRO decisions. CMS data on external reviews show that enrollees win roughly 40 to 60% of external reviews when clinical documentation is strong. [8]

Step 4: State insurance commissioner complaint. Filing a complaint with your state's department of insurance creates a formal record and often prompts a second look from Anthem's compliance team.

Cost-Saving Programs When Insurance Falls Short

Even with coverage, Lantus can be expensive. Several programs reduce the cost.

Sanofi Valyou Savings Program. Commercially insured patients who meet income eligibility criteria may pay as little as $99 per month for a 30-day supply of Lantus through this manufacturer-sponsored program. Enrollment is available at sanofi.us. This program does not apply to government-insured patients (Medicare, Medicaid, TRICARE).

Insulin.org (a Life for a Child program). For uninsured or underinsured patients, this nonprofit connects individuals with free or heavily discounted insulin.

Mark Cuban's Cost Plus Drugs. As of 2024, Cost Plus Drugs (costplusdrugs.com) lists generic insulin glargine (biosimilar) for approximately $30, $50 per vial, a viable option for patients paying cash.

Pharmacy discount cards. GoodRx, RxSaver, and Blink Health sometimes negotiate prices below your Anthem copay for Tier 3 drugs, although you generally cannot combine these with insurance simultaneously.

The American Diabetes Association maintains an updated list of insulin affordability resources, including emergency supply programs run by Sanofi, Novo Nordisk, and Eli Lilly. [9]

How Anthem's Formulary Compares to ADA Clinical Guidelines

The 2024 ADA Standards of Medical Care in Diabetes state: "Insulin is necessary for patients with type 1 diabetes and may be needed by many patients with type 2 diabetes to achieve glycemic targets." [10] The ADA does not mandate any specific insulin glargine brand, but it does emphasize continuity of care and the importance of avoiding cost-driven non-adherence.

A 2021 study in Diabetes Care (N=1 to 893 U.S. adults with insulin-treated diabetes) found that 24.4% reported cost-related insulin non-adherence within the prior 12 months, including rationing doses and delaying refills. [11] Cost-related non-adherence is independently associated with worse glycemic control and higher rates of diabetes-related emergency department visits, making insurance coverage optimization a direct patient-safety concern.

The 2023 Endocrine Society Clinical Practice Guideline on Diabetes Technology notes that formulary restrictions that force abrupt insulin switches without clinical supervision can destabilize glucose control in patients who have been titrated over months, particularly those using continuous glucose monitoring (CGM). [12] If you use a CGM and have been carefully titrated on Lantus, that CGM data is powerful documentation to include in a PA request.

Anthem Medicare Advantage and Lantus: The $35 Cap Explained

If you have an Anthem Medicare Advantage plan with Part D drug coverage, the rules changed meaningfully on January 1, 2023. Section 11406 of the Inflation Reduction Act capped out-of-pocket insulin costs at $35 per month per covered insulin product for all Part D enrollees. Lantus is covered under Part D when it appears on your plan's formulary.

However, if your Anthem Medicare Advantage plan does not list Lantus on its formulary because a biosimilar has replaced it, you will still pay no more than $35 per month for the biosimilar that is listed. In that scenario, switching to the listed product is likely your most cost-effective path. Request a formulary exception if your physician documents a clinical reason you need Lantus specifically, and even if denied, the $35 cap will apply to the exception if granted.

For Part B coverage of insulin used with an insulin pump, the rules differ. Insulin administered through a durable medical equipment (DME) pump is covered under Part B rather than Part D, and the $35 cap may not automatically apply unless your plan has extended it. Confirm with Anthem's Medicare member services line.

When Lantus May Not Be the Right Choice Regardless of Coverage

Coverage questions aside, your endocrinologist or primary care physician may recommend switching away from Lantus for purely clinical reasons. Newer basal insulins, including insulin degludec (Tresiba) and insulin glargine U-300 (Toujeo), offer longer durations of action and flatter pharmacokinetic profiles that reduce nocturnal hypoglycemia risk in some patients.

The BRIGHT trial (N=929) compared insulin glargine U-300 versus insulin degludec U-200 in insulin-naive type 2 diabetes patients and found comparable HbA1c reductions but different hypoglycemia rates at different points in the titration period. Reported in Diabetes Care in 2018, HbA1c fell by 1.4% in both arms at 24 weeks, with glargine U-300 showing lower hypoglycemia rates during the titration phase and degludec showing lower rates in the maintenance phase. [13]

If you are switching from Lantus to a next-generation basal insulin, note that Toujeo (glargine U-300) requires a dose conversion: the starting dose of Toujeo is the same unit count as your Lantus dose, but because of higher concentration, you may need adjustment over the first several weeks.

Practical Checklist Before Your Next Anthem Prescription Fill

Use this list to avoid delays and unexpected costs at the pharmacy counter.

1. Confirm Lantus is on your current year's Anthem formulary before the prescription is sent.
2. Ask your prescriber's office to check for PA or step-therapy requirements proactively.
3. If step therapy applies, ask your prescriber whether a biosimilar switch is clinically appropriate for you.
4. Enroll in the Sanofi Valyou Savings Program if you are commercially insured and cost is a concern.
5. Keep a 30-day emergency supply if possible, especially before January 1 formulary resets.
6. Request a 90-day supply at a preferred mail-order pharmacy (Anthem often discounts 90-day fills).
7. If denied, initiate the peer-to-peer review within five business days of receiving the denial letter.

The FDA's guidance on insulin biosimilars and interchangeability is a useful patient resource for understanding what interchangeability means and does not mean in practice. [14]